Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.22.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

Three Months Ended

March 31, 2022

(000’s)

   

Three Months Ended

March 31, 2021

(000’s)

 

Revenues (from external customers)

               

BioSig

  $ 8     $ 118  

ViralClear

    -       -  

NeuroClear

    -       -  
    $ 8     $ 118  
                 

Operating Expenses

               

BioSig

  $ 7,749     $ 7,774  

ViralClear

    322       805  

NeuroClear

    2       -  
    $ 8,073     $ 8,579  
                 

Loss from operations

               

BioSig

  $ (7,741

)

  $ (7,754

)

ViralClear

    (322

)

    (805

)

NeuroClear

    (2

)

    -  
    $ (8,065

)

  $ (8,559

)

 

   

March 31, 2022

   

December 31, 2021

 

Total Assets

               

BioSig

  $ 11,951     $ 13,595  

ViralClear

    591       1,924  

NeuroClear

    -       -  
    $ 12,542     $ 15,519